Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Immunity ; 53(4): 840-851.e6, 2020 10 13.
Article in English | MEDLINE | ID: mdl-33053332

ABSTRACT

Activating precursor B cell receptors of HIV-1 broadly neutralizing antibodies requires specifically designed immunogens. Here, we compared the abilities of three such germline-targeting immunogens against the VRC01-class receptors to activate the targeted B cells in transgenic mice expressing the germline VH of the VRC01 antibody but diverse mouse light chains. Immunogen-specific VRC01-like B cells were isolated at different time points after immunization, their VH and VL genes were sequenced, and the corresponding antibodies characterized. VRC01 B cell sub-populations with distinct cross-reactivity properties were activated by each immunogen, and these differences correlated with distinct biophysical and biochemical features of the germline-targeting immunogens. Our study indicates that the design of effective immunogens to activate B cell receptors leading to protective HIV-1 antibodies will require a better understanding of how the biophysical properties of the epitope and its surrounding surface on the germline-targeting immunogen influence its interaction with the available receptor variants in vivo.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens/immunology , B-Lymphocytes/immunology , Broadly Neutralizing Antibodies/immunology , Epitopes, B-Lymphocyte/immunology , HIV Antibodies/immunology , HIV-1/immunology , Receptors, Antigen, B-Cell/immunology , Amino Acid Sequence , Animals , Antibodies, Neutralizing/immunology , Cell Line , Female , Germ Cells/immunology , HEK293 Cells , HIV Infections/immunology , Humans , Male , Mice, Transgenic
SELECTION OF CITATIONS
SEARCH DETAIL
...